Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.

导出 LinkOut

翻译打印收藏纠错

第一作者： Meagan,Montesion

第一单位： Foundation Medicine, Inc., Cambridge, Massachusetts.

作者： Meagan,Montesion ^[1] ; Karthikeyan,Murugesan ^[1] ; Dexter X,Jin ^[1] ; Radwa,Sharaf ^[1] ; Nora,Sanchez ^[1] ; Ameet,Guria ^[1] ; Max,Minker ^[1] ; Gerald,Li ^[1] ; Virginia,Fisher ^[1] ; Ethan S,Sokol ^[1] ; Dean C,Pavlick ^[1] ; Jay A,Moore ^[1] ; Alan,Braly ^[1] ; Gaurav,Singal ^[1] ; David,Fabrizio ^[1] ; Leah A,Comment ^[1] ; Naiyer A,Rizvi ^[2] ; Brian M,Alexander ^[1] ; Garrett M,Frampton ^[1] ; Priti S,Hegde ^[1] ; Lee A,Albacker ^[3]

作者单位： Foundation Medicine, Inc., Cambridge, Massachusetts. ^[1] Columbia University Irving Medical Center, New York, New York. ^[2] Foundation Medicine, Inc., Cambridge, Massachusetts. lalbacker@foundationmedicine.com. ^[3]

主题词癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);HLA抗原(HLA Antigens);人类(Humans);肺肿瘤(Lung Neoplasms);突变(Mutation);肿瘤逃逸(Tumor Escape)

DOI 10.1158/2159-8290.CD-20-0672

PMID 33127846

发布时间 2022-01-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交